Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer
Conclusion: More routinely available TME, SIR and tumor markers alone and in combination deliver reliable prognostic data for choosing the patients with higher risk for propagation. CMS4 is linked with high TSR and poor prognosis, but in overall, CMS-classification showed only limited effect on SIR- and tumor-markers.PMID:38645565 | PMC:PMC11026638 | DOI:10.3389/pore.2024.1611574 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 22, 2024 Category: Pathology Authors: Anna Jakab Árpád V Patai M ónika Darvas Karolina Torm ássi-Bély Tam ás Micsik Source Type: research
Retraction: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma
Pathol Oncol Res. 2024 Apr 5;30:1611784. doi: 10.3389/pore.2024.1611784. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.3389/pore.2023.1611204.].PMID:38645566 | PMC:PMC11027495 | DOI:10.3389/pore.2024.1611784 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 22, 2024 Category: Pathology Authors: Pathology and Oncology Research Editorial Office Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting
Pathol Oncol Res. 2024 Mar 28;30:1611590. doi: 10.3389/pore.2024.1611590. eCollection 2024.ABSTRACTLung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation sequencing technologies are available for library generation: 1) anchored multiplex-, 2) amplicon based- and 3) hybrid capture-based-PCR. Anchored multiplex PCR-based sequencing was investigated for routine molecular testing within the national Network Genomic Medicine Lung Cancer (nNGM). Four centers applied ...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: J örg Kumbrink Melanie-Christin Demes Jan Jeroch Andreas Br äuninger Kristin Hartung Uwe Gerstenmaier Ralf Marienfeld Axel Hillmer Nadine Bohn Christina Lehning Ferdinand Ferch Peter Wild Stefan Gattenl öhner Peter M öller Frederick Klauschen Andreas Source Type: research
Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2
Pathol Oncol Res. 2024 Mar 28;30:1611767. doi: 10.3389/pore.2024.1611767. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1007/s12253-017-0298-z.].PMID:38605930 | PMC:PMC11007041 | DOI:10.3389/pore.2024.1611767 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting
Pathol Oncol Res. 2024 Mar 28;30:1611590. doi: 10.3389/pore.2024.1611590. eCollection 2024.ABSTRACTLung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation sequencing technologies are available for library generation: 1) anchored multiplex-, 2) amplicon based- and 3) hybrid capture-based-PCR. Anchored multiplex PCR-based sequencing was investigated for routine molecular testing within the national Network Genomic Medicine Lung Cancer (nNGM). Four centers applied ...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: J örg Kumbrink Melanie-Christin Demes Jan Jeroch Andreas Br äuninger Kristin Hartung Uwe Gerstenmaier Ralf Marienfeld Axel Hillmer Nadine Bohn Christina Lehning Ferdinand Ferch Peter Wild Stefan Gattenl öhner Peter M öller Frederick Klauschen Andreas Source Type: research
Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2
Pathol Oncol Res. 2024 Mar 28;30:1611767. doi: 10.3389/pore.2024.1611767. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1007/s12253-017-0298-z.].PMID:38605930 | PMC:PMC11007041 | DOI:10.3389/pore.2024.1611767 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting
Pathol Oncol Res. 2024 Mar 28;30:1611590. doi: 10.3389/pore.2024.1611590. eCollection 2024.ABSTRACTLung cancer is a paradigm for a genetically driven tumor. A variety of drugs were developed targeting specific biomarkers requiring testing for tumor genetic alterations in relevant biomarkers. Different next-generation sequencing technologies are available for library generation: 1) anchored multiplex-, 2) amplicon based- and 3) hybrid capture-based-PCR. Anchored multiplex PCR-based sequencing was investigated for routine molecular testing within the national Network Genomic Medicine Lung Cancer (nNGM). Four centers applied ...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: J örg Kumbrink Melanie-Christin Demes Jan Jeroch Andreas Br äuninger Kristin Hartung Uwe Gerstenmaier Ralf Marienfeld Axel Hillmer Nadine Bohn Christina Lehning Ferdinand Ferch Peter Wild Stefan Gattenl öhner Peter M öller Frederick Klauschen Andreas Source Type: research
Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2
Pathol Oncol Res. 2024 Mar 28;30:1611767. doi: 10.3389/pore.2024.1611767. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1007/s12253-017-0298-z.].PMID:38605930 | PMC:PMC11007041 | DOI:10.3389/pore.2024.1611767 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Pathology & Oncology Research Editorial Office Source Type: research
Intestinal Langerhans cell histiocytosis presenting with symptoms similar to inflammatory bowel disease: a case report
CONCLUSION: The clinical symptoms of Langerhans cell histiocytosis involving the gastrointestinal tract are not specific and may resemble symptoms observed in inflammatory bowel disease and other primary gastrointestinal tumors. Therefore, in cases of infants presenting with inflammatory gastrointestinal symptoms that do not resolve after treatment, a biopsy is essential to obtain a differential diagnosis.PMID:38605931 | PMC:PMC11007090 | DOI:10.3389/pore.2024.1611705 (Source: Pathology Oncology Research)
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Yuqing Liu Zhenwei Chen Lu Wang Baizhou Li Source Type: research
Targeted therapeutic options in early and metastatic NSCLC-overview
Pathol Oncol Res. 2024 Mar 28;30:1611715. doi: 10.3389/pore.2024.1611715. eCollection 2024.ABSTRACTThe complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measure...
Source: Pathology Oncology Research - April 12, 2024 Category: Pathology Authors: Gabriella G álffy Éva Morócz R éka Korompay R éka Hécz R éka Bujdosó Rita Pusk ás T ímea Lovas Eszter G áspár Kamel Yahya P éter Király Zolt án Lohinai Source Type: research
